Differences in tumor necrosis factor-α soluble receptor serum concentrations between patients with Henoch-Schonlein purpura and pediatric systemic lupus erythematosus: Pathogenetic implications

Journal of Rheumatology

Volumn 25, Issue 2, 1998, Pages 361-365

  Gattorno, Marco ^c   Picco, Paolo ^a   Barbano, Giancarlo ^a   Stalla, Franca ^a   Sormani, Maria Pia ^a   Buoncompagni, Antonella ^a   Gusmano, Rosanna ^a   Borrone, Carla ^a   Pistoia, Vito ^b  

^a Department of Pediatric Nephrology ^*

^b Laboratory of Pediatric Oncology

^c G GASLINI INSTITUTE   (Italy)

Author keywords

Henoch Schonlein purpura; Pediatric systemic lupus erythematosus; Tumor necrosis factor pathogenesis

Indexed keywords

CD3 ANTIGEN; CELL MARKER; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; T LYMPHOCYTE RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNOVIAL FLUID; T LYMPHOCYTE SUBPOPULATION;

EID: 0031888635     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Johnson KJ, Ward PA. Role of oxygen metabolites in immune complex injury of lung. J Immunol 1981;126:2363-9.
2. Till GO, Johnson KJ, Kunkel R, Ward PA. Intravascular activation of complement and acute lung injury. Dependency on neutrophil and toxic oxygen metabolites. J Clin Invest 1982;69:1126-35.
3. Mulligan MS, Hevel JM, Marietta MA, Ward PA. Tissue injury caused by deposition of immune complexes is 1-arginine dependent. Proc Natl Acad Sci USA 1991;88:6338-42.
4. Warren JS, Yabroff KR, Remick DG, et al. Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in rats. J Clin Invest 1989;84:1873-82.
5. Mulligan MS, Varani J, Dame MK, et al. Role of ELAM-1 in neutrophil mediated lung injury. J Clin Invest 1991;88:1396-406.
6. Mulligan MS, Vaporciyan AA, Miyasaka M, Tamatani T, Ward PA. Tumor necrosis factor a regulates in vivo intrapulmonary expression of ICAM-1. Am J Pathol 1993;142:1739-48.
7. Mulligan MS, Warran JF, Smith CW, et al. Lung injury after deposition of IgA immune complexes. Requirements for CD18 and L-Arginine. J Immunol 1992;148:3086-92.
8. Warren JS, Barton PA, Jones ML. Contrasting roles for tumor necrosis factor in the pathogenesis of IgG and IgA immune complex lung injury. Am J Pathol 1991;138:581-7.
9. Mulligan MS, Ward PA. Immune complex-induced lung and dermal injury: Differing requirements for TNF-α and IL-1. J Immunol 1992;149:331-6.
10. Jacob CO, McDevid HO. Tumor necrosis factor-a in murine autoimmune "lupus" erythematosus nephritis. Nature 1988;331:356-8.
11. Boswell JM, Yui MA, Burt DW, Kelley VE. Increased tumor necrosis factor and IL-1 β gene expression in the kidneys of mice with lupus nephritis. J Immunol 1988;141:3050-4.
12. Belmont HM, Abramson SB, Lie IT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996;39:9-22.
13. Allen DM, Diamond LK, Howell DA. Anaphylactoid purpura in children. Am J Dis Child 1960;99:833-54.
14. Emery H, Larter W, Schaller JG. Henoch-Schönlein vasculitis. Arthritis Rheum 1977;20:385-8.
15. Ilan Y, Naparstek Y. Schönlein-Henoch syndrome in adults and children. Semin Arthritis Rheum 1991;21:103-9.
16. Mills JA, Bloch A, Calabrese LH, et al. The ACR 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum 1990;33:1114-21.
17. Jennette JC, Falk U, Andrassay K, et al. Nomenclature of systemic vasculitides. Proposal of an International Consensus Conference. Arthritis Rheum 1994;37:187-92.
18. Brockhaus M, Schoenfeld DJ, Schlaeger EJ, Hunziker W, Lesslaner W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 1990;87:3127-31.
19. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
20. Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in development of an activity score. Clin Exp Rheumatol 1992;10:541-7.
21. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang C and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: A disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
22. Gattorno M, Buoncompagni A, Molinari AC, et al. Antiphospholipid antibodies in pediatric SLE, JCA and overlap syndromes. SLE patients with both lupus anticoagulant and high titre anti-cardiolipin antibodies are at risk for clinical manifestations related to antiphospholipid syndrome. Br J Rheumatol 1995;34:873-81.
23. Gattorno M, Picco P, Buoncompagni A, et al. Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann Rheum Dis 1996;55:243-7.
24. Grau GE. The influence of soluble receptors in cytokine measurement. J NIH Res 1995;7:82.
25. Aderka D, Wysenbeek A, Engelmaun H, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993;36:1111-20.
26. Heilig B, Fiehn C, Brockhaus M, Gallati H, Pezzuto A, Hunstein W. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematosus, progressive systemic sclerosis and mixed connective tissue disease. J Clin Immunol 1993;13:321-8.
27. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35:1160-9.
28. Furukawa S, Matsubara T, Yone K, Hirano Y, Okumura K, Yabuta K. Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumor necrosis factor-α and interleukin 6 in serum. Eur J Pediatr 1992;151:44-7.
29. Cope AP, Maini RN. Soluble tumor necrosis factor receptors in arthritis. J Rheumatol 1995;22:382-4.
30. Aversa G, Punnonen J, DeVries J. The 26-Kd transmembrane form of tumor necrosis factor-α on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation. J Exp Med 1993;177:1575-85.
31. Macchia D, Almerigogna F, Paronchi P, Ravina A, Maggi F, Romagnani S. Membrane tumor necrosis factor-α is involved in the polyclonal B-cell activation induced by MW-infected human T cells. Nature 1993;363:464-6.
32. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 1991;285:199-212.
33. Lantz M, Malik S, Slevin ML, Olsson I. Infusion of tumor necrosis factor causes an increase in circulating TNF-binding protein in humans. Cytokines 1992;2:402-6.
34. Higuchi M, Aggarwaal BB. TNF induces internalization of p60 and shedding of the p80 receptor. J Immunol 1994;152:3550-8.